Sofosbuvir and velpatasvir

The biotechnology market is growing rapidly due to investments, M&A, and tech advancements, with a focus on innovative therapies and AI. Stocks like Regeneron, Biogen, and Gilead show promise. The market is expected to reach $8.01 trillion by 2035, driven by innovation and advanced therapies.

Top 20 biopharmaceutical companies saw a 2% market cap increase in Q3 2024, driven by FDA approvals and strategic alliances. Bristol Myers Squibb led with a 24.6% growth, fueled by Cobenfy's approval and a $3.5bn deal with Prime Medicine. Gilead Sciences and Sanofi also grew significantly due to new drug approvals. Despite some declines, industry recovery is expected, supported by Federal Reserve interest rate cuts.